NewEdge Advisors LLC Has $27.81 Million Stock Holdings in Abbott Laboratories $ABT

NewEdge Advisors LLC trimmed its stake in shares of Abbott Laboratories (NYSE:ABT) by 6.3% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 270,877 shares of the healthcare product maker’s stock after selling 18,291 shares during the quarter. NewEdge Advisors LLC’s holdings in Abbott Laboratories were worth $27,811,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also modified their holdings of ABT. MidAtlantic Capital Management Inc. bought a new position in shares of Abbott Laboratories during the fourth quarter valued at $25,000. Cornerstone Financial Management LLC acquired a new position in Abbott Laboratories in the fourth quarter valued at about $25,000. Purpose Unlimited Inc. bought a new stake in Abbott Laboratories during the fourth quarter worth about $25,000. Portfolio Resources Advisor Group Inc. bought a new stake in Abbott Laboratories during the fourth quarter worth about $26,000. Finally, Abound Financial LLC bought a new position in shares of Abbott Laboratories in the fourth quarter valued at approximately $26,000. 75.18% of the stock is owned by institutional investors and hedge funds.

Abbott Laboratories Trading Down 0.1%

Shares of ABT opened at $107.81 on Friday. The stock’s fifty day simple moving average is $95.51 and its 200-day simple moving average is $100.03. The company has a quick ratio of 0.97, a current ratio of 1.38 and a debt-to-equity ratio of 0.57. The firm has a market capitalization of $186.56 billion, a PE ratio of 34.89, a price-to-earnings-growth ratio of 2.09 and a beta of 0.59. Abbott Laboratories has a 12-month low of $81.97 and a 12-month high of $137.49.

Abbott Laboratories (NYSE:ABT) last announced its quarterly earnings data on Thursday, July 16th. The healthcare product maker reported $1.31 earnings per share for the quarter, topping the consensus estimate of $1.28 by $0.03. Abbott Laboratories had a return on equity of 17.69% and a net margin of 11.65%.The firm had revenue of $12.59 billion during the quarter, compared to analysts’ expectations of $12.52 billion. During the same period in the previous year, the business posted $1.26 EPS. The company’s quarterly revenue was up 13.0% compared to the same quarter last year. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. As a group, research analysts predict that Abbott Laboratories will post 5.52 earnings per share for the current year.

Abbott Laboratories Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, August 17th. Stockholders of record on Wednesday, July 15th will be given a $0.63 dividend. This represents a $2.52 annualized dividend and a dividend yield of 2.3%. The ex-dividend date is Wednesday, July 15th. Abbott Laboratories’s dividend payout ratio (DPR) is currently 81.55%.

Wall Street Analysts Forecast Growth

ABT has been the topic of a number of research analyst reports. Stifel Nicolaus decreased their price target on Abbott Laboratories from $145.00 to $120.00 and set a “buy” rating on the stock in a research report on Friday, April 17th. Weiss Ratings lowered Abbott Laboratories from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Thursday, July 23rd. Jefferies Financial Group lowered their target price on Abbott Laboratories from $145.00 to $135.00 and set a “buy” rating for the company in a research note on Friday, April 17th. Bank of America cut their price target on Abbott Laboratories from $120.00 to $102.00 in a report on Friday, June 12th. Finally, Robert W. Baird assumed coverage on shares of Abbott Laboratories in a report on Wednesday, July 1st. They set an “outperform” rating and a $121.00 price objective on the stock. Three investment analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $118.17.

Abbott Laboratories News Roundup

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Diagnostics expansion strengthens growth outlook: Abbott is broadening its Diagnostics growth base through its Exact Sciences relationship and oncology testing expansion. Gains in cancer diagnostics and resilient routine testing are helping offset weaker respiratory-related demand, potentially making growth less dependent on COVID and respiratory testing. Here’s How ABT Broadens Diagnostics Growth Base With Oncology Expansion
• Positive Sentiment: Analysts remain bullish: Although ABT has lagged the broader market over the past year, Wall Street analysts continue to view the stock favorably and see further upside potential based on Abbott’s diversified healthcare portfolio and earnings durability. Abbott Stock: Is Wall Street Bullish or Bearish?
• Positive Sentiment: Reliable-growth investment case: An investor letter from Matrix Asset Advisors presents Abbott as a compelling long-term healthcare holding, emphasizing its dependable growth profile and diversified end markets. Broader nutritional-market growth could also support Abbott’s nutrition business over time. What Makes Abbott Laboratories a Compelling Investment Opportunity Global Nutritional Market Outlook
• Neutral Sentiment: Value debate remains: Comparisons with Envista (NVST) focus on which medical-products stock offers better value. The coverage may prompt investors to weigh Abbott’s premium valuation against its stronger diversification and consistency, but it does not represent a new company-specific catalyst. NVST vs. ABT: Which Stock Is the Better Value Option?
• Neutral Sentiment: Competitive backdrop: Analysts’ discussion of Abbott alongside other healthcare companies provides sector context, but no major change to Abbott’s outlook is indicated. Boston Scientific’s reduced 2026 guidance could be relatively favorable for Abbott if investors rotate toward companies with steadier execution, though it also underscores competitive pressures in medical devices. Analysts Offer Insights on Healthcare Companies

Abbott Laboratories Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.